Bill Creech Email & Phone Number

Preparing to launch a game changing product for screening antioxidants through the skin in < 30 seconds! Now you can determine whether your life style, diet and supplement program are actually working.

Innovative partnership with Pharmanex to provide clinicians quantitative measurement of antioxidants through the skin in less than 30 seconds. Manage nutrition and supplementation to the highest degree while adding revenue to the practice.

St Louis, Missouri, Us

BacterioScan, Inc. is a medical device company dedicated to changing the way infectious disease is diagnosed and treated. We are driven by a fundamental desire to ensure the successful use of antibiotics. We are launching the 216Dx UTI System, the first FDA cleared solution for UTI Detection. Fast, accurate and affordable, the award-winning BacterioScan 216Dx transforms the way urinary tract infections are diagnosed. The 216Dx detects and precisely measures bacterial growth indicative of a UTI, from clinical urine specimens in just 3 hours.

PHDx integrates precision diagnostics with an innovative wellness programto attack chronic disease progression and improve healthcare outcomesover time by tracking and monitoring therapeutic response. We are in a exciting position to grow clinical lab testing for a cutting edge physician- patient relationship which asks how and why illness occurs and restores health by addressing the root causes of disease for each individual.

Delphi is introducing leading edge diagnostics for patients with advanced breast cancer and will expand to meet the diagnostic needs of other cancers.

Cambridge, Ma, Us

Our vision is to empower patients and physicians with better ways to manage and care for chronic disease. Our mission is to deliver more proactive, precise diagnostics to manage cancer and other chronic diseases.Nuclea provides clinical testing services in our high complexity CLIA/CAP labs located in Massachusetts, including the HER-2/neu IVD diagnostic kit for quantification and monitoring of HER-2/neu oncoprotein levels in serum. We offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome.Accomplishments in 2015-• 2015 revenue increased 79.3% over 2014 • Q4 2015 increased 192% vs Q4 2014• Q4 2015 increased 92% vs Q3 2015• Implemented pricing program for 2016 that will increase revenue and GP >10% & 15%• Implemented commercialization plan for FDA cleared devices and CLIA lab services• Developed 3 year business plan to raise private equity investment

Dubai , Ae

ERBA Diagnostics Inc., is a part of the global ERBA Mannheim Group. The company is vertically integrated and specializes in manufacture and marketing of proprietary diagnostic reagents, test kits and instrumentation in the areas of autoimmune, chemistry, hematology, urinalysis, diabetes and infectious disease. Responsible for all aspects of commercial activities for the Americas. 37 direct/indirect reportsAccomplishments- • Planned & executed successful AACC after just 6 weeks on the job• Expanded Latin American sales and Customer Service Department• Developed pricing and distribution plan for 2015• Led effort to sign 4 major national distributor Partners to add select Erba products • Planned market launch for first US based chemistry analyzer

Trumbull, Connecticut, Us

Responsible for the overall commercialization strategy of the novel blood diagnostic test, OVA1. Developed and managed all sales and marketing efforts for the first IVDMIA cleared by the FDA, along with the OvaCalc™ algorithm. Corporate officer for Vermillion reporting to the CEO, provided cross functional support for the corporation including preparing for all aspects of public company compliance and reporting. 17 Direct reports. • Developed a successful pricing strategy with Quest Diagnostics that exceeded the market expectations by 5X.• Recruited and built the sales and marketing team • Executed the commercialization plan in concert with Quest Diagnostics.• Gained support of >25% of specialty Gynecologic Oncology surgeons in US within 24 months.• Planning and implementation of the KOL bureau with over 30 speakers and 200 programs • Attained of 2% market share (MS) within 18 months of launch • Planning of CPT coding, payer coverage such as Humana/Aetna/DoD/ BCBS TX and reimbursement process for OVA1 through Medicare• Successfully developed product web site www.ova-1.com for physicians and patients in addition to launching a social media campaign: Facebook page for patient awareness w/ >13K followers

Us

Responsible for sales, marketing and customer support in $35+M subsidiary. Channels include direct, distribution, OEM and direct consumer sales. Responsibilities include field service group for high speed, value add instrumentation. Products include commodity and value add, patent protected plastics used in the clinical, dairy and employee drug-testing markets. 16 direct reports.

Responsible for setting corporate policy on national accounts, contract negotiations, marketing and coordinating efforts of 15 major subsidiaries in the clinical market. Interface with Presidents of each subsidiary for planning, contract pricing, positioning and market development in $1B business.

Abbott Park, Illinois, Us